Dr. Reddy’s Laboratories (RDY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Dr. Reddy’s Laboratories (“Dr. Reddy’s” or the “Company”) (NYSE: RDY) investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN DR. REDDY’S LABORATORIES (RDY), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [e-mail], by telephone at [phone] or visit our website at www.howardsmithlaw.com.

What Happened?

On July 22, 2026, Dr. Reddy’s announced its first quarter fiscal 2027 earnings, reporting, among other things, earnings per share of only $0.06, due in part to the adverse impact of a ₹2.4 billion provision related to out-of-specification semaglutide batches. CEO Erez Israeli said, “The quarter's EBITDA margin was adversely impacted by semaglutide-related challenges, including lower sales, provision for rejected batches, loss of production-linked incentives and other associated costs.”

On this news, the price of Dr. Reddy’s Laboratories stock price fell $1.18, or 9.4%, to close at $11.38 on July 22, 2026, thereby injuring investors.

Contact Us To Participate or Learn More:

If you purchased Dr. Reddy’s Laboratories securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: [phone]
Email: [e-mail],
Visit our website at: www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.